Literature DB >> 8005276

Comparison between depot and standard release triptoreline in in vitro fertilization: pituitary sensitivity, luteal function, pregnancy outcome, and perinatal results.

E Porcu1, L Dal Prato, R Seracchioli, R Fabbri, M Longhi, C Flamigni.   

Abstract

OBJECTIVE: To compare the effects of depot and standard release form of triptoreline in superovulation induction in IVF programs.
DESIGN: One hundred ninety-six patients undergoing IVF were randomized between two treatment groups. Pituitary desensitization was obtained in group 1 (102 patients) with a single IM injection of 3.75 mg D-Trp-6-luteinizing hormone-releasing hormone (LH-RH) and, in group 2 (94 patients), with daily SC administration of 0.1 mg D-Trp-6-LH-RH. In a subgroup of 11 patients, a series of GnRH tests was performed to investigate pituitary desensitization and, in another subgroup of 12 patients, a study of luteal phase steroid profile was performed. In an additional 23 patients, a series of GnRH tests were performed to investigate pituitary desensitization during the late follicular and midluteal phases.
RESULTS: No differences were found in the time necessary to reach desensitization (11.3 +/- 1.03 versus 11.3 +/- 1.45 days; mean +/- SEM), whereas resumption of pituitary activity takes place in 7 days after the discontinuation of the daily form and in about 2 months after discontinuation of the depot form. No differences were found in the duration of stimulation, number of FSH ampules, E2 levels, and number of follicles (11.7 +/- 0.68, versus 12.2 +/- 0.68) on hCG administration day and the total oocytes collected (9.1 +/- 0.6 versus 9.2 +/- 0.64). Oocyte quality, percentage of fertilization and cleavage, pregnancy rate per transfer (28.7% versus 25.6%), and miscarriages (about 30%) were similar in the two protocols. No difference was found in hormonal levels during the luteal phase. In both groups there was a high incidence of multiple pregnancy.
CONCLUSION: Comparable results can be achieved with both long-acting and standard-release forms of GnRH analogs in patients undergoing assisted reproduction in terms of follicular stimulation and abortion rates despite differences in the duration of pituitary suppression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8005276     DOI: 10.1016/s0015-0282(16)56827-7

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  6 in total

1.  Ongoing pregnancy after intracytoplasmic sperm injection of epididymal spermatozoa into cryopreserved human oocytes.

Authors:  E Porcu; R Fabbri; P M Ciotti; S Petracchi; R Seracchioli; C Flamigni
Journal:  J Assist Reprod Genet       Date:  1999-05       Impact factor: 3.412

Review 2.  Timing luteal support in assisted reproductive technology: a systematic review.

Authors:  Matthew T Connell; Jennifer M Szatkowski; Nancy Terry; Alan H DeCherney; Anthony M Propst; Micah J Hill
Journal:  Fertil Steril       Date:  2015-01-29       Impact factor: 7.329

3.  Differences in serum LH and FSH levels using depot or daily GnRH agonists in controlled ovarian stimulation: influence on ovarian response and outcome of ART.

Authors:  Barbara Sonntag; Ludwig Kiesel; Eberhard Nieschlag; Hermann M Behre
Journal:  J Assist Reprod Genet       Date:  2005-08       Impact factor: 3.412

Review 4.  Depot versus daily administration of gonadotrophin-releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles.

Authors:  Luiz Eduardo T Albuquerque; Leopoldo O Tso; Humberto Saconato; Maria Cecília R M Albuquerque; Cristiane R Macedo
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

5.  Comparison between depot leuprorelin and daily buserelin in IVF.

Authors:  E Porcu; M Filicori; L Dal Prato; R Fabbri; R Seracchioli; C Colombi; C Flamigni
Journal:  J Assist Reprod Genet       Date:  1995-01       Impact factor: 3.412

6.  The follicular-phase depot GnRH agonist protocol results in a higher live birth rate without discernible differences in luteal function and child health versus the daily mid-luteal GnRH agonist protocol: a single-centre, retrospective, propensity score matched cohort study.

Authors:  Ying Zhang; Wenxian Zhao; Yifan Han; Xin Chen; Shaoyuan Xu; Yueyue Hu; Honglu Diao; Changjun Zhang
Journal:  Reprod Biol Endocrinol       Date:  2022-09-19       Impact factor: 4.982

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.